Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Ramaswamy Govindan, Bob T. Li et al.|New England Journal of Medicine|2021Cited by 1.8k
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim resultsChristine D. Palmer, Karin Jooss, Amy Rappaport et al.|Nature Medicine|2022Cited by 225
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Jacob Sands et al.|Journal of Clinical Oncology|2023Cited by 168